ProCE Banner Activity

SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib

Conference Coverage
Slideset

Analysis of the primary efficacy population in the phase II SAVANNAH trial suggests that savolitinib plus osimertinib may be an efficacious and manageable treatment option for select patients with EGFRm NSCLC and MET overexpression or amplification after disease progression on osimertinib.

Released: April 02, 2025

Expiration: October 01, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc